Commenting on the publication of the NHS Mandate, Carol Blount, NHS Partnerships Director, said: “We welcome the publication of the Mandate from the Government to NHS England. A key development of the Mandate is the inclusion of a specific commitment to deliver the Innovation Health and Wealth (IHW) agenda, which aligns to the recently agreed Pharmaceutical Price Regulation Scheme (PPRS) Heads of Agreement."
Carol added: "We are pleased to see that many helpful elements of the previous Mandate have also been retained, such as the objective to ensure patients get access to treatments, including those drugs recommended by NICE. Other retained elements of interest are the commitment to promote research and innovation, and the role of the NHS in supporting the economy and the Strategy for Life Sciences.
“The PPRS agreement provides a unique opportunity for the NHS to ensure that patients in this country are able to access innovative medicines, as we currently lag behind other countries in this regard. We have already said that this agreement needs to go hand-in-hand with action by the Government and the NHS to ensure patients have access to the best medicines, and the full implementation of the IHW agenda plays a key part. The ABPI will continue its conversations with key stakeholders to ensure that the roles of NHS England and NICE are not duplicated when it comes to assessing the cost-effectiveness of medicines.”